《大行報告》瑞銀上調敏華(01999.HK)目標價至22.5元 評級「買入」
瑞銀發表報告指,敏華(01999.HK)上半年業績超過該行和市場預期。收入按年增長54%至102.14億元,比該行和共識分別高5%和10%。經調整後的凈利潤達到9.91億元,亦比該行和共識分別高3%和6%,經調整後的凈利潤率為9.7%,按年下降2.7個百分點,與該行和共識一致,主要是由於海外運輸成本上升,拖累凈利潤率下降3個百分點。
瑞銀認為,盡管受到疫情影響,敏華出口收入仍按年增長66%,證明海外市場需求強勁,該行認為出口最差情況已經過去。隨著疫情逐步改善和航運的正常化,預計敏華的出口業務將回升,維持「買入」評級,目標價由22.2元上調至22.5元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.